• Ambea launched a takeover of Humana, offering SEK 20 cash, 0.305 Ambea shares, and one CVR-instrument per Humana share.
• Offer value set at SEK 62.3 per share, valuing Humana at about SEK 2.96 billion, excluding any contingent payout.
• CVR-instrument ties to 80% of any damages award in Humana’s Swedish state lawsuit; maximum indicated payout SEK 4.36 per CVR-instrument.
• Acceptance period expected to run from about Aug. 25, 2026 to about Sept. 30, 2026, subject to extensions.
• Shareholders representing about 41.9% have committed to accept on certain conditions; BDO issued a fairness opinion calling terms financially fair.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humana AB published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.